Collaboration Agreement (Tables)

12 Months Ended

Dec. 31, 2015

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Collaboration Revenue

Collaboration revenue was as follows:

	Years Ended December 31,
	2015		2014		2013
Collaboration revenue:
Related to U.S. XTANDI net sales	$	575,658	$	339,902	$	196,208
Related to ex-U.S. XTANDI net sales		119,778		49,476		6,338
Related to upfront and milestone payments		247,822		321,109		70,396
Total	$	943,258	$	710,487	$	272,942

Schedule of Collaboration Revenue Related to U.S. XTANDI Net Sales

Collaboration revenue related to U.S. XTANDI net sales was as follows:

	Years Ended December 31,
	2015			2014			2013
U.S. XTANDI net sales (as reported by Astellas)	$	1,151,317		$	679,805		$	392,415
Shared U.S. development and commercialization costs		(375,008	)		(323,730	)		(241,106	)
Pre-tax U.S. profit	$	776,309		$	356,075		$	151,309
Medivation’s share of pre-tax U.S. profit	$	388,154		$	178,037		$	75,655
Reimbursement of Medivation’s share of shared U.S. costs		187,504			161,865			120,553
Collaboration revenue related to U.S. XTANDI net sales	$	575,658		$	339,902		$	196,208

Schedule of Collaboration Revenue Related to Upfront and Milestone Payments

Collaboration revenue related to upfront and milestone payments from Astellas was as follows:

	Years Ended December 31,
	2015		2014		2013
Sales milestones earned	$	245,000	$	50,000	$	25,000
Development milestones earned		—		257,000		20,000
Amortization of deferred upfront and development    milestones		2,822		14,109		25,396
Total	$	247,822	$	321,109	$	70,396